We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue

Cryotherapy Device Treats Heavy Menstrual Bleeding

By HospiMedica International staff writers
Posted on 16 Apr 2019
Print article
Image: The Cerene cryotherapy device is designed to reduce menstrual bleeding (Photo courtesy of Channel Medsystems).
Image: The Cerene cryotherapy device is designed to reduce menstrual bleeding (Photo courtesy of Channel Medsystems).
A novel nitrous oxide (N2O) cryotherapy device freezes the lining of the uterus in order to significantly reduce future menstrual bleeding.

The Channel Medsystems (Emeryville, CA, USA) Cerene cryotherapy device is indicated for endometrial cryoablation in premenopausal women with heavy menstrual bleeding due to benign causes, and for whom child bearing is complete. The cryothermic energy is provided by a liquid-to-gas phase change of N2O; during the 2½ minute treatment cycle, liquid N2O delivered from a small cylinder located in the device handle flows through a delivery line and into an inflow line with multiple jets. The liquid N2O is infused into an ultra-thin polyurethane liner, where it converts into gas and is exhausted from the bottom of the handle.

An exhaust collection bag transfers the gas to the conformable liner that enables close coverage of the irregular surfaces of the uterine cavity and provides an effective thermal transfer. Prior to cryotherapy delivery, the liner is inserted into the uterine cavity to the appropriate length--between 2.5 and 6.5 cm, based upon prior uterine sound measurements--inside a thermally insulating sheath. Once in position, the user rotates a knob to retract the insulating sheath; the retraction also controls the number of eventual N2O jets exposed within the liner.

The liner is gradually pressurized with filtered air, deflated, and re-pressurized a second time. Once a final leak detection test is completed, N2O flow is automatically initiated. After 2½ minutes, N2O flow is stopped and the user is prompted to rotate a twist ring to vent the remaining gas. The uterine cavity is allowed to thaw, and vacuum is initiated within the liner to expedite device removal. After use, the entire device and the exhaust collection bag are disposed of. Sequential operating instructions and device status are continuously displayed on the device’s LCD Screen.

“The Cerene Device provides gynecologists with the first realistic option for treatment in their office, a setting that is more comfortable for women and significantly less expensive for the healthcare system,” said Ric Cote, President and CEO of Channel Medsystems. “The shift away from the operating room that the Cerene Device enables could potentially reduce the cost to treat heavy menstrual bleeding by hundreds of millions of dollars annually.”

“Women who suffer from heavy menstrual bleeding are seeking safe and effective treatments that are well tolerated with minimal inconvenience. Channel Medsystems has developed a treatment that is easy to use, is reproducible in any setting of care, and is very well tolerated without anesthesia,” said Ted Anderson, MD, PhD, of Vanderbilt University Medical Center. “The development of new technology like the Cerene Device could allow gynecologists to provide a safe, effective, affordable, and convenient treatment to the millions of women who seek care for heavy menstrual bleeding.”

Cryoablation, the use of extreme cold to destroy tissue, is a well-characterized, durable therapy routinely used to ablate malignant and benign cardiac, liver, breast, and prostate tissue, among others. In the uterus, the use of cryothermic energy has been shown to reduce the likelihood of scarring and intrauterine adhesions that are often associated with heat-based treatments, which may contribute to the development of long-term complications, including re-operation and, ultimately, the failure of endometrial ablation.

Related Links:
Channel Medsystems

Print article



view channel

Hillrom Acquires Bardy Diagnostics to Expand into Ambulatory Cardiac Monitoring Segment

Hillrom (Chicago, IL, USA) has reached a definitive agreement to acquire Bardy Diagnostics, Inc. (BardyDx; Seattle, WA, USA) for a cash consideration of USD 375 million. The acquisition of BardyDx,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.